StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Xeljanz (tofacitinib by Year

Xeljanz (tofacitinib — rheumatoid arthritis / ulcerative colitis) — International operational (constant-currency) YoY (%) (%)

QuarterlyAnnual

Pfizer Xeljanz (tofacitinib: -6.0% in FY2025, up 3.0 pts from a year earlier.

Latest, FY2025
-6.0%
Period ended Dec 31, 2025
Change on a year earlier
+3.0 pts
-9.0% in FY2024
History
9 years
Since FY2017
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| Xeljanz | 1,087 | 1,168 | (7%) | (7%) | 625 | 680 | (8%) | 462 | 488 | (5%) | (6%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedXeljanz (tofacitinib — rheumatoid arthritis / ulcerative colitis) — International operational (constant-currency) YoY (%) (%)Year on yearSource
FY2025Dec 31, 2025-6.0%+3.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024-9.0%+4.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2023Dec 31, 2023-13.0%-6.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
FY2022Dec 31, 2022-7.0%-22.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
FY2021Dec 31, 202115.0%-7.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
FY2020Dec 31, 202022.0%-18.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗
FY2019Dec 31, 201940.0%-44.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312019xex99.htm, filed 2020-01-28) ↗
FY2018Dec 31, 201884.0%+8.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312018xex99.htm, filed 2019-01-29) ↗
FY2017Dec 31, 201776.0%–Form 8-K (Earnings / Guidance Release) (pfe-12312017xex99.htm, filed 2018-01-30) ↗

Cite this data

StockData. (2026). Pfizer Xeljanz (tofacitinib (%), annual FY2017–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/xeljanz-oper-intl

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.